DiscGenics

  • Total Funding$68 M

OverviewSuggest Edit

DiscGenics is a biopharmaceutical company focused on developing regenerative therapies aimed at alleviating pain and restoring function in patients with diseases of the spine. Its product candidate IDCT is a homologous, allogeneic, injectable cell therapy for the treatment of patients with degenerative disc disease.
TypePrivate
Founded2007
HQSalt Lake City, UT, USMap
Websitediscgenics.com

Recent NewsAll News

Latest Updates

Employees (est.) (Aug 2022)42
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at DiscGenics

Flagg Flanagan

Flagg Flanagan

Chairman & CEO
Kevin T. Foley

Kevin T. Foley

Chief Medical Officer, Director
Najeeb Thomas

Najeeb Thomas

Director
Bob Wynalek

Bob Wynalek

Chief Operating & Commercialization Officer, Director
Jeff Poole

Jeff Poole

Chief Financial Officer
Show more

DiscGenics Office Locations

DiscGenics has an office in Salt Lake City
Salt Lake City, UT, US (HQ)
5940 Harold Gatty Dr
Salt Lake City, UT, US
675 Arapeen Dr #106
Show all (2)

DiscGenics Financials and Metrics

Summary Metrics

Founding Date

2007

DiscGenics total Funding

$68 m

DiscGenics latest funding size

$50 m

Time since last funding

2 years ago

DiscGenics investors

Mitsubishi UFJ Capital, CareNet Group, Ci:z Investment LLP, Eagle Fund SP1 LLP, Medical Incubator Japan, Mitsubishi UFJ Capital Co.
DiscGenics's latest funding round in August 2020 was reported to be $50 m. In total, DiscGenics has raised $68 m
Show all financial metrics

DiscGenics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

Learn more about our premium products
SecurityScorecard logo

DiscGenics Online and Social Media Presence

DiscGenics's Trends

Embed Graph

DiscGenics News and Updates

January 05, 2022

DiscGenics to Present at 40th Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, Jan. 5, 2022 /PRNewswire/ -- DiscGenics, Inc., a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced...
October 18, 2021

DiscGenics Honored by Goldman Sachs for Entrepreneurship

SALT LAKE CITY, Oct. 18, 2021 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that Goldman...

 DiscGenics Frequently Asked Questions

  • When was DiscGenics founded?

    DiscGenics was founded in 2007.

  • Who are DiscGenics key executives?

    DiscGenics's key executives are Flagg Flanagan, Kevin T. Foley and Najeeb Thomas.

  • How many employees does DiscGenics have?

    DiscGenics has 42 employees.

  • Who are DiscGenics competitors?

    Competitors of DiscGenics include InGeneron, Kamada Pharmaceuticals and JCR Pharmaceuticals.

  • Where is DiscGenics headquarters?

    DiscGenics headquarters is located at 5940 Harold Gatty Dr, Salt Lake City.

  • Where are DiscGenics offices?

    DiscGenics has an office in Salt Lake City.

  • How many offices does DiscGenics have?

    DiscGenics has 2 offices.